PMID- 26219615
OWN - NLM
STAT- MEDLINE
DCOM- 20160905
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 21
IP  - 32
DP  - 2015
TI  - New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non 
      Small Cell Lung Cancer.
PG  - 4763-72
AB  - Lung cancer is the leading cause of death from cancer worldwide with limited 
      available treatment options in absence of specific molecular alteration. New 
      therapeutic approaches for addressing non small cell lung cancer (NSCLC) are 
      urgently needed. Angiogenesis plays a central role in the tumor growth and 
      metastatic dissemination which stimulates multiple cells to build new abnormal 
      microvessels and leads to tumor microenvironment alterations. This process 
      involves many factors, such as, the vascular endothelial growth factor (VEGF) 
      that has a dominant role, the fibroblast growth factors (FGFs) and the 
      plateled-derived growth factor (PDGF) that together contribute to resistance to 
      VEGF/VEGFR- directed therapy. To date, bevacizumab is currently the only 
      angiogenesis inhibitor that has been approved for the treatment of patients with 
      advanced NSCLC in first-line setting. Moreover, in the last year, two new 
      antiangiogenic agents have been approved for the treatment of patients with 
      advanced NSCLC in second line setting. This review describes the new 
      antiangiogenic agents in the treatment of advanced NSCLC.
FAU - Sacco, Paola Claudia
AU  - Sacco PC
FAU - Maione, Paolo
AU  - Maione P
FAU - Rossi, Antonio
AU  - Rossi A
FAU - Sgambato, Assunta
AU  - Sgambato A
FAU - Casaluce, Francesca
AU  - Casaluce F
FAU - Palazzolo, Giovanni
AU  - Palazzolo G
FAU - Gridelli, Cesare
AU  - Gridelli C
AD  - Division of Medical Oncology, "S.G.Moscati" Hospital, Avellino, Italy. 
      cgridelli@libero.it.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/administration & dosage/adverse effects/*therapeutic use
MH  - Bevacizumab/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Neovascularization, Pathologic/*drug therapy/pathology
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
EDAT- 2015/07/30 06:00
MHDA- 2016/09/07 06:00
CRDT- 2015/07/30 06:00
PHST- 2015/06/01 00:00 [received]
PHST- 2015/07/28 00:00 [accepted]
PHST- 2015/07/30 06:00 [entrez]
PHST- 2015/07/30 06:00 [pubmed]
PHST- 2016/09/07 06:00 [medline]
AID - CPD-EPUB-69154 [pii]
AID - 10.2174/1381612821666150729120009 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2015;21(32):4763-72. doi: 10.2174/1381612821666150729120009.